REG - Ergomed plc - Director/PDMR Shareholding

ErgomedAnnouncement

13/06/2019 07:06

RNS Number : 0319C
Ergomed plc
13 June 2019
 


Ergomed Plc
("Ergomed" or the "Company")
 
PDMR Dealing
 
Ergomed, a company focused on providing specialised services to the pharmaceutical industry, announces that on 12 June 2019, Richard Barfield, Chief Financial Officer of the Company, purchased 64,000 ordinary shares of 1 pence each in the Company ("Share(s)") at a price of 270 pence per Share (the "Purchase").
 
Following the Purchase, Richard Barfield's holding in the Company is 100,000 Shares (representing 0.21 per cent. of the Company's issued share capital).
 
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
 
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
 



1


Details of the person discharging managerial responsibilities/person closely associated




a)


Name


Richard Barfield




2


Reason for the notification




a)


Position/status


Chief Financial Officer




b)


Initial notification /Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


Ergomed Plc




b)


Legal Entity Identifier


213800BVS8I9VMC1AP84




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a)


Description of the financial instrument, type of instrument
 
Identification code


Ordinary shares of 1 pence each
 
 
 GB00BN7ZCY67




b)


Nature of the transaction


Purchase of Shares




c)


Currency


GBP




d)


Price(s) and volume(s)


Price(s)


Volume(s)




270 pence


64,000














e)


Aggregated information
- Aggregated volume
- Price
- Aggregated total


Volume: 64,000 ordinary shares of 1 pence each, purchase price of 270 pence per share
Aggregated: £172,800.00
 




f)


Date of the transaction


12 June 2019




g)


Place of the transaction


London Stock Exchange, AIM



 
Enquiries:



Ergomed plc


 Tel: +44 (0) 1483 402 975




Miroslav Reljanović (Executive Chairman)




























Numis Securities Limited


Tel: +44 (0) 20 7260 1000




Freddie Barnfield / Huw Jeremy (Nominated Adviser)








James Black (Broker)


















Consilium Strategic Communications - for UK enquiries


Tel: +44 (0) 20 3709 5700




Chris Gardner / Mary-Jane Elliott


ergomed@consilium-comms.com




Matthew Neal / Olivia Manser


















MC Services - for Continental European enquiries


Tel: +49 211 5292 5222




Anne Hennecke







 
About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance solutions, integrated under the PrimeVigilance brand, and a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com.
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHKMGMVNZGGLZM